Precision Medicine Trends Will Expand PROTAC Applications Despite Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
06 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$63.50
88.2% undervalued intrinsic discount21 Aug
US$7.48
1Y
-72.1%7D
4.3%1Y
-72.1%7D
4.3%